CY1106983T1 - ΕΜΒΟΛΙΟ ΠΕΠΤΙΔΑΣΗΣ C5a ΣΤΡΕΠΤΟΚΟΚΚΟΥ - Google Patents

ΕΜΒΟΛΙΟ ΠΕΠΤΙΔΑΣΗΣ C5a ΣΤΡΕΠΤΟΚΟΚΚΟΥ

Info

Publication number
CY1106983T1
CY1106983T1 CY20071101432T CY071101432T CY1106983T1 CY 1106983 T1 CY1106983 T1 CY 1106983T1 CY 20071101432 T CY20071101432 T CY 20071101432T CY 071101432 T CY071101432 T CY 071101432T CY 1106983 T1 CY1106983 T1 CY 1106983T1
Authority
CY
Cyprus
Prior art keywords
vaccine
streptococcus
scp
aspiration
disclosed
Prior art date
Application number
CY20071101432T
Other languages
English (en)
Inventor
Paul Patrick Cleary
Deborah K Stafslien
Original Assignee
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of Minnesota filed Critical Regents Of The University Of Minnesota
Publication of CY1106983T1 publication Critical patent/CY1106983T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Exposure Control For Cameras (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτονται νέα εμβόλια για χρήση κατά του αποικισμού ή της μολύνσεως από το β-αιμολυτικό στρεπτόκοκκο. Τα εμβόλια περιέχουν μία ανοσογόνο ποσότητα μίας παραλλαγής της πεπτιδάσης C5a στρεπτοκόκκου (SCP). Αποκαλύπτεται επίσης μία μέθοδος για την προστασία ενός ευπαθούς ζώου από τον αποικισμό ή τη μόλυνση από β-αιμολυτικό στρεπτόκοκκο δια χορηγήσεως ενός τέτοιου εμβολίου. Περαιτέρω αποκαλύπτεται μία ενζυματικά ανενεργός SCP και πολυνουκλεοτίδια τα οποία κωδικοποιούν αυτές τις πρωτεΐνες SCP.
CY20071101432T 1998-12-07 2007-11-08 ΕΜΒΟΛΙΟ ΠΕΠΤΙΔΑΣΗΣ C5a ΣΤΡΕΠΤΟΚΟΚΚΟΥ CY1106983T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/206,898 US6355255B1 (en) 1998-12-07 1998-12-07 Streptococcal C5a peptidase vaccine
EP99966013A EP1137785B8 (en) 1998-12-07 1999-12-03 STREPTOCOCCAL C5a PEPTIDASE VACCINE

Publications (1)

Publication Number Publication Date
CY1106983T1 true CY1106983T1 (el) 2012-09-26

Family

ID=43662233

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101432T CY1106983T1 (el) 1998-12-07 2007-11-08 ΕΜΒΟΛΙΟ ΠΕΠΤΙΔΑΣΗΣ C5a ΣΤΡΕΠΤΟΚΟΚΚΟΥ

Country Status (18)

Country Link
US (4) US6355255B1 (el)
EP (3) EP2308981B1 (el)
JP (2) JP5122703B2 (el)
KR (1) KR100777502B1 (el)
CN (2) CN1679929B (el)
AT (2) ATE503017T1 (el)
AU (2) AU779085B2 (el)
BR (1) BRPI9915988B8 (el)
CA (1) CA2354508C (el)
CY (1) CY1106983T1 (el)
DE (2) DE69936877T2 (el)
DK (3) DK1892298T3 (el)
ES (3) ES2293745T3 (el)
IL (2) IL143289A0 (el)
MX (1) MXPA01005757A (el)
PT (3) PT1892298E (el)
SI (2) SI2308981T1 (el)
WO (1) WO2000034487A1 (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US7256265B2 (en) * 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
EP2277894A1 (en) * 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
WO2004094468A2 (en) * 2003-04-23 2004-11-04 Hansa Medical Ab Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
EP1812057A4 (en) 2004-11-01 2009-07-22 Brigham & Womens Hospital MODIFIED STREPTOCOCCAL POLYSACCHARIDES AND USES THEREOF
GB2428006A (en) * 2005-07-07 2007-01-17 Jevgenis Morov AMI-3 vaccine comprising group A Streptococcus pyogenes bacteria
US7596254B2 (en) * 2006-03-17 2009-09-29 William Marsh Rice University Intra-operative 3-D reconstruction of bone cement boli using X-rays
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
DK2032698T3 (da) * 2006-06-23 2012-09-03 Danisco Us Inc Systematisk bedømmelse af sekvens- og aktivitetsforbindelse ved anvendelse af stedbedømmelsesbiblioteker til manipulation af flere egenskaber
US20080311129A1 (en) * 2006-11-02 2008-12-18 Camas Incorporated Adherence inhibitor directed to and method of making and using
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
LT2144924T (lt) * 2007-04-16 2016-10-10 Minervax Aps Sulieto baltymo vakcina
CN101969992B (zh) 2007-09-12 2014-10-01 诺华股份有限公司 Gas57突变型抗原和gas57抗体
AU2009313615B2 (en) 2008-11-05 2012-11-29 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
EP3626263A1 (en) 2010-06-04 2020-03-25 Wyeth LLC Vaccine formulations
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
MY166172A (en) 2010-09-10 2018-06-07 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102746388B (zh) * 2012-07-02 2014-06-25 中山大学 一种链球菌保护性抗原C5a及其制备方法
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
KR101905278B1 (ko) 2013-09-08 2018-10-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
KR101775093B1 (ko) 2016-05-31 2017-09-19 그린코스 주식회사 베타인살리실레이트와 폴리에틸렌글리콜을 포함하는 각질 용해 화장품 조성물, 그 제조 방법, 및 이를 포함하는 화장품
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CN106822885B (zh) * 2017-02-16 2020-06-30 清华大学 肺炎链球菌疫苗
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
CN109045292A (zh) * 2018-11-08 2018-12-21 山东大学 一种a群链球菌寡糖蛋白缀合物及其制备方法与应用
KR102165688B1 (ko) 2020-04-03 2020-10-14 주식회사 퀀타매트릭스 그람 양성균 배양용 배양액
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152411A (en) * 1977-07-27 1979-05-01 Akzona Incorporated High specific activity labeled substances
DE2964721D1 (en) 1978-08-24 1983-03-17 Nat Res Dev Pasteurellosis vaccines
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4695562A (en) 1984-04-06 1987-09-22 Univ. Of Tennessee Research Corp. Synthetic peptide compounds
US4772584A (en) 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
EP0272929B1 (en) 1986-12-24 1996-03-20 Genentech, Inc. Enkephalinase for therapeutic use
US5162226A (en) 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5124153A (en) 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
DE68926427T2 (de) 1988-03-25 1996-12-05 Univ Rockefeller Vom streptococcus m-protein abgeleitete synthetische peptide und damit hergestellte impfstoffe
US4863159A (en) 1988-03-25 1989-09-05 Morrison Molded Fiber Glass Company Apparatus for use in the exercise of the human body
DE69113049T2 (de) 1990-07-31 1996-04-04 Genentech, Inc., South San Francisco, Calif. Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
JPH07502896A (ja) 1992-01-08 1995-03-30 ザ ロックフェラー ユニバーシティ 連鎖球菌の多官能性表面タンパク
NZ251096A (en) 1992-03-09 1996-03-26 Univ California Sialyltransferases and compositions and methods for their identification and synthesis
WO1993021220A1 (en) 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
IL106922A (en) 1992-09-14 1998-08-16 Novartis Ag Complex materials with one or more wettable surfaces and a process for their preparation
EP0618813B1 (en) 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigen of hybrid m protein and carrier for group a streptococcal vaccine
DK0625043T3 (da) 1992-09-16 2002-04-22 Univ Tennessee Res Corp Vaccine med rekombinant multivalent M-protein
US5866135A (en) 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5679654A (en) 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5618129A (en) 1995-03-13 1997-04-08 Paragon Electric Company, Inc. Snap-engaging mounting plate
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist

Also Published As

Publication number Publication date
KR20010082326A (ko) 2001-08-29
BRPI9915988B8 (pt) 2021-05-25
US20050136068A1 (en) 2005-06-23
EP1892298A1 (en) 2008-02-27
DE69936877T2 (de) 2008-04-30
CA2354508C (en) 2011-02-01
ES2363446T3 (es) 2011-08-04
PT1892298E (pt) 2011-06-01
IL143289A (en) 2011-11-30
US6951653B2 (en) 2005-10-04
DK2308981T3 (da) 2013-05-13
DK1137785T3 (da) 2007-12-10
CA2354508A1 (en) 2000-06-15
JP2012072153A (ja) 2012-04-12
CN1679929A (zh) 2005-10-12
EP1137785A1 (en) 2001-10-04
MXPA01005757A (es) 2002-04-24
AU2004231164B2 (en) 2008-05-01
SI1892298T1 (sl) 2011-08-31
BRPI9915988B1 (pt) 2015-08-18
EP2308981A1 (en) 2011-04-13
EP2308981B1 (en) 2013-02-13
EP1137785B8 (en) 2007-11-21
JP2002531584A (ja) 2002-09-24
IL143289A0 (en) 2002-04-21
PT1137785E (pt) 2007-10-22
AU779085B2 (en) 2005-01-06
US8440205B2 (en) 2013-05-14
US6355255B1 (en) 2002-03-12
EP1137785B1 (en) 2007-08-15
ATE503017T1 (de) 2011-04-15
US7635483B2 (en) 2009-12-22
EP1892298B1 (en) 2011-03-23
AU2004231164A1 (en) 2004-12-09
DK1892298T3 (da) 2011-06-14
US20040062777A1 (en) 2004-04-01
CN100389198C (zh) 2008-05-21
BR9915988A (pt) 2001-09-04
ES2293745T3 (es) 2008-03-16
DE69943305D1 (de) 2011-05-05
DE69936877D1 (de) 2007-09-27
CN1679929B (zh) 2012-09-26
AU2166500A (en) 2000-06-26
ES2401998T3 (es) 2013-04-26
PT2308981E (pt) 2013-02-21
CN1329669A (zh) 2002-01-02
WO2000034487A1 (en) 2000-06-15
KR100777502B1 (ko) 2007-11-16
US20060153879A1 (en) 2006-07-13
JP5122703B2 (ja) 2013-01-16
ATE370237T1 (de) 2007-09-15
SI2308981T1 (sl) 2013-04-30

Similar Documents

Publication Publication Date Title
CY1106983T1 (el) ΕΜΒΟΛΙΟ ΠΕΠΤΙΔΑΣΗΣ C5a ΣΤΡΕΠΤΟΚΟΚΚΟΥ
PT877624E (pt) Vacina de c5a peptidase estreptococica
PT1203817E (pt) Compostos e metodos para imunoterapia e le diagnostic de tuberculose
FI960977A (fi) Bakteeriperäiset eksportoidut proteiinit ja niihin perustuvat asellulaariset rokotteet
LV10203A (lv) Panemiens inficesanas ar AIDS noteiksanai olbaltumvielu kompozicija test-komplekts
DK22389D0 (da) Fremgangsmaade og middel til beskyttelse mod sygdomme foraarsaget af mikroorganismer, navnlig mycoplasma
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
HUP0301634A2 (hu) Hőmérséklet-érzékeny, élő vakcina Mycoplasma hyopneumoniaera
EA200100700A1 (ru) Гены и белки и их применение
DK0775746T3 (da) Vaccine mod fjerkræcoccidiose
DE69629812D1 (de) Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
DK0651609T3 (da) Pasteurella multocida toxoidvacciner
SE9903534D0 (sv) Vaccin
DE69824794D1 (de) Streptococcus equi Impfstoff
ES2063897T5 (es) Vacuna contra el virus del colera porcino y diagnostico.
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
EA200100701A1 (ru) Белки наружной поверхности, их гены и их применение
ATE111356T1 (de) Impfstoff gegen schweinedysenterie.
MX9604262A (es) Antigenos de pasteurellaceae y vacunas relacionadas.
EP0178928A3 (en) Vaccines